PLUS THERAPEUTICS INC
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
CNSY$0.68+19.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| For the Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows used in operating activities: | ||
| Net loss | $(9,075) | $(9,506) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 524 | 477 |
| Amortization of deferred financing costs and debt discount | 20 | 160 |
| Share-based compensation expense | 422 | 428 |
| Accretion of discount on short-term investments | (70) | — |
| Non-cash financing expense | 3,545 | — |
| Change in fair value of warrants | (5,654) | — |
| Loss on disposal of property and equipment | — | 2 |
| Amortization of operating lease right-of-use assets | 96 | 86 |
| Stock issued for research and development | — | 75 |
| Increases (decreases) in cash caused by changes in operating assets and liabilities: | ||
| Grant receivable | — | (91) |
| Other current assets | 704 | 3,190 |
| Accounts payable and accrued expenses | 1,326 | (4,061) |
| Change in operating lease liabilities | (97) | (87) |
| Deferred grant liability | (1,084) | (1,643) |
| Net cash used in operating activities | (9,343) | (10,970) |
| Cash flows used in investing activities: | ||
| Purchases of property and equipment | (135) | (118) |
| Redemption of short-term investments | 3,650 | — |
| Purchase of short-term investments | (7,145) | — |
| Purchase of intangible assets | (545) | — |
| Net cash used in investing activities | (4,175) | (118) |
| Cash flows provided by financing activities: | ||
| Principal payments of term loan obligation | (3,996) | (1,206) |
| Proceeds from credit facility | 3,292 | — |
| Purchase of treasury stock | (374) | — |
| Proceeds from sale of common stock, net of offering costs of $0.2 million | — | 5,180 |
| Proceeds from sale of common stock, warrants and pre-funded warrants, net | 7,265 | — |
| Net cash provided by financing activities | 6,187 | 3,974 |
| Net decrease in cash and cash equivalents | (7,331) | (7,114) |
| Cash and cash equivalents at beginning of period | 8,554 | 18,120 |
| Cash and cash equivalents at end of period | $1,223 | $11,006 |
| Supplemental disclosure of cash flows information: | ||
| Cash paid during period for: | ||
| Interest | $32 | $186 |
| Supplemental schedule of non-cash investing and financing activities: | ||
| Unpaid offering cost | $— | $1 |
| Right-of-use assets obtained in exchange for operating lease liability | $— | $71 |
| Common stock issued in payment for in process research and development | $— | $75 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.